Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended	3 Months Ended		0 Months Ended			12 Months Ended
	Jul. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 09, 2014	Apr. 03, 2015	Feb. 03, 2015	Dec. 31, 2014	Jan. 30, 2015
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		$ 6,059,111					$ 7,810,417
Allowance for doubtful accounts		2,226,890					2,071,706
Revenue from pharmaceutical clients		462,093	577,381
Line of credit, borrowing base percentage of pharmaceutical accounts receivable		80.00%
Line of credit, interest above prime rate		2.25%	1.75%
Line of credit, interest charged		5.50%	5.00%
Line of credit, amount drawn		1,465,662					1,500,000
Advertising costs		17,124	6,422
Payment period from the date of invoice		45 days
Cash and cash equivalents that exceeded federally insured limits		1,476,222
Bad debt expense		1,902,144	1,293,850
Cash, Uninsured Amount		7,803
Line of Credit Facility, Maximum Borrowing Capacity	2,000,000	8,500,000
Line of Credit Facility, Commitment Fee Amount	750,000
Allowance For Doubtful Accounts Percentage Of Accounts Receivable		100.00%					100.00%
Debt Instrument, Unamortized Discount		703,507					536,150
Stockholders Equity Attributable to Parent, Total		(4,937,113)					(1,170,107)
Medicare Program [Member]
Significant Accounting Policies [Line Items]
Percentage Of Revenue		42.00%	39.00%
Licensing Agreements [Member]
Significant Accounting Policies [Line Items]
License Costs		5,508	10,961
Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	681,090							681,090
Fair value Of Warrants Issued	414,239
Conversion of Stock Conversion Price Per Share	$ 0.61
Fair Value Assumptions, Risk Free Interest Rate	2.01%
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	101.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.936
First Amendment Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		576,923
Fair value Of Warrants Issued		167,712
Conversion of Stock Conversion Price Per Share		$ 0.29
Fair Value Assumptions, Risk Free Interest Rate		1.39%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value Assumptions, Expected Volatility Rate		90.90%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.39
Replacement Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.39
SG Financial LLC [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility, Current Borrowing Capacity				2,500,000
Line of Credit Facility, Commitment Fee Amount				1,029,412
Loans Payable				8,500,000
SG Financial LLC [Member] | Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				200,321
Subsequent Event [Member] | First Amendment Warrant [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility,Agreement Date					Apr. 03, 2015
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,702,702
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.37
SWK Credit Agreement [Member]
Significant Accounting Policies [Line Items]
Long-term Debt, Gross	12,000,000
Line of Credit Facility, Interest Rate Description		The Loan bears interest at a rate equal to the LIBOR Rate (as defined in the SWK Credit Agreement) plus an applicable margin of 12.5% per annum, subject to a one percent (1.0%) LIBOR floor. Interest on the Loan is due and payable in arrears (i) on the forty-fifth
Loans Payable	8,500,000
Debt Issuance Cost							576,161
Adjustments to Additional Paid in Capital, Warrant Issued							377,140
Deferred Finance Costs, Net							187,092
Line of Credit Facility, Remaining Borrowing Capacity						10,000,000
Line of Credit Facility, Increase (Decrease), Net						1,500,000
Debt Instrument, Unamortized Discount						599,305
Stockholders Equity Attributable to Parent, Total						23,144
Debt Instrument, Interest Rate, Stated Percentage		13.50%					13.50%
SWK Credit Agreement [Member] | Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility, Commitment Fee Amount					2,000,000
SWK First Amendment Credit Agreement [Member]
Significant Accounting Policies [Line Items]
Loans Payable		1,500,000
Debt Issuance Cost		168,372
Adjustments to Additional Paid in Capital, Warrant Issued		148,887
Deferred Finance Costs, Net		19,485
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage		70.00%					73.00%
Roche Molecular Systems [Member]
Significant Accounting Policies [Line Items]
Royalty Expense		16,265	44,373
Clinical [Member]
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		454,773					1,037,834
Silicon Valley Bank [Member]
Significant Accounting Policies [Line Items]
Mortgage Loans on Real Estate, Final Maturity Date		Jul. 25, 2016
Line of Credit Facility, Maximum Borrowing Capacity		463,677					500,000
Line Of Credit Facility Covenant Compliance Liquidity Amount		$ 1,000,000